Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
- Status
- COMPLETED
- Phase
- PHASE2
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
- Status
- TERMINATED
- Phase
- PHASE1
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Pomalidomide for Chronic Graft-versus-Host Disease
- Status
- COMPLETED
- Phase
- PHASE2
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
- Status
- COMPLETED
- Phase
- PHASE1